董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Les Funtleyder | 男 | Director,Interim Chief Executive Officer and Chief Financial Officer | 55 | 3.02万 | 未持股 | 2025-11-09 |
| Stacy J. Kanter | 女 | Director | 66 | 未披露 | 未持股 | 2025-11-09 |
| Jay S. Skyler | 男 | Director | 78 | 未披露 | 未持股 | 2025-11-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Les Funtleyder | 男 | Director,Interim Chief Executive Officer and Chief Financial Officer | 55 | 3.02万 | 未持股 | 2025-11-09 |
| Catherine Thorpe | 女 | Interim Chief Accounting Officer | 62 | 未披露 | 未持股 | 2025-11-09 |
| Constantine Chinoporos | 男 | Chief Operating Officer and Chief Business Officer | 58 | 未披露 | 未持股 | 2025-11-09 |
| Dale Hooks | 男 | Chief Commercial Officer | 58 | 未披露 | 未持股 | 2025-11-09 |
| Evan P. Bailey | 男 | Chief Medical Officer | 44 | 未披露 | 未持股 | 2025-11-09 |
董事简历
中英对照 | 中文 | 英文- Les Funtleyder
-
Les Funtleyder自2018年12月起担任我们的临时首席财务官，自2016年6月起担任我们的董事会成员。Funtleyder先生还自2014年1月起担任E Squared Capital Management，LLC的梦百合投资组合经理，自2017年6月起担任麦肯锡公司（McKinsey and Co.）的高级外部顾问，自2013年12月起担任私募股权梦百合基金BlueCloud Health的咨询合伙人。Funtleyder之前曾担任Opko Health Inc.（一家公开上市的梦百合公司）战略投资和通信主管。Funtleyder先生目前在几家私营梦百合公司和基金会的董事会任职。Funtleyder先生也是Columbia University Medical Center的兼职教授。Funtleyder先生在杜兰大学（Tulane University）获得学士学位，在哥伦比亚大学邮差公共卫生学院（Columbia University Mailman School of Public Health）获得硕士学位。
Les Funtleyder has served as a member of Board since December 2020. Mr. Funtleyder has served as a member of the board of directors of Applied Therapeutics Inc. (NASDAQ: APLT), a clinical stage biopharmaceutical company, since June 2016 and served as its interim Chief Financial Officer from December 2018 to April 2019. Mr. Funtleyder has also served as a healthcare portfolio manager at E Squared Capital Management, LLC since January 2014, a senior external advisor with McKinsey and Co. since June 2017, and a consulting partner at Bluecloud Health, a private equity healthcare fund, since December 2013. Mr. Funtleyder previoly served as the director of strategic investments and communications of OPKO Health Inc. (NASDAQ: OPK), a publicly traded healthcare company, from April 2014 to June 2016. Mr. Funtleyder currently serves on the board of directors of several private healthcare companies and foundations. Mr. Funtleyder is also an adjunct professor of Healthcare Investing at Columbia University's School of Public Health. Mr. Funtleyder received his B.A. from Tulane University and MPH from Columbia University Mailman School of Public Health. - Les Funtleyder自2018年12月起担任我们的临时首席财务官，自2016年6月起担任我们的董事会成员。Funtleyder先生还自2014年1月起担任E Squared Capital Management，LLC的梦百合投资组合经理，自2017年6月起担任麦肯锡公司（McKinsey and Co.）的高级外部顾问，自2013年12月起担任私募股权梦百合基金BlueCloud Health的咨询合伙人。Funtleyder之前曾担任Opko Health Inc.（一家公开上市的梦百合公司）战略投资和通信主管。Funtleyder先生目前在几家私营梦百合公司和基金会的董事会任职。Funtleyder先生也是Columbia University Medical Center的兼职教授。Funtleyder先生在杜兰大学（Tulane University）获得学士学位，在哥伦比亚大学邮差公共卫生学院（Columbia University Mailman School of Public Health）获得硕士学位。
- Les Funtleyder has served as a member of Board since December 2020. Mr. Funtleyder has served as a member of the board of directors of Applied Therapeutics Inc. (NASDAQ: APLT), a clinical stage biopharmaceutical company, since June 2016 and served as its interim Chief Financial Officer from December 2018 to April 2019. Mr. Funtleyder has also served as a healthcare portfolio manager at E Squared Capital Management, LLC since January 2014, a senior external advisor with McKinsey and Co. since June 2017, and a consulting partner at Bluecloud Health, a private equity healthcare fund, since December 2013. Mr. Funtleyder previoly served as the director of strategic investments and communications of OPKO Health Inc. (NASDAQ: OPK), a publicly traded healthcare company, from April 2014 to June 2016. Mr. Funtleyder currently serves on the board of directors of several private healthcare companies and foundations. Mr. Funtleyder is also an adjunct professor of Healthcare Investing at Columbia University's School of Public Health. Mr. Funtleyder received his B.A. from Tulane University and MPH from Columbia University Mailman School of Public Health.
- Stacy J. Kanter
-
在根据《交易法》将我们的普通股注册为一类证券生效之前，StacyJ.Kanter立即成为我们的董事会成员。Kanter女士在Skadden，Arps，Slate，Meagher&Flom LLP从事法律执业超过30年，她于1993年至2018年12月担任合伙人，并于2009年至2018年12月担任全球资本市场业务主管，自2019年1月起担任法律顾问。Kanter女士还担任Skadden全球多样性和包容性委员会主席。1984年至1986年和1988年至1993年，Kanter女士是Skadden的合伙人。Kanter女士从1986年到1987年担任纽约东区美国地方法院法官Raymond J.Dearie阁下的书记官。Kanter女士在奥尔巴尼商学院（University at Albany School of Business）获得工商管理学士学位，并在布鲁克林法学院（Brooklyn Law School）获得法学博士学位。
Stacy J. Kanter,is also currently serving as a member of the board of directors of Oppenheimer Holdings Inc. (NYSE: OPY) since October 2023. Ms. Kanter practiced law for more than 30 years with Skadden, Arps, Slate, Meagher & Flom LLP ("Skadden"), where she was a partner from 1993 until December 2018, Head of the Global Capital Markets practice from 2009 until December 2018 and was Of Counsel from January 2019 until May 2019. Ms. Kanter also chaired Skadden's Global Diversity and Inclusion Committee. Ms. Kanter was an associate at Skadden from 1984 to 1986 and from 1988 to 1993. Ms. Kanter served as a law clerk to the Honorable Raymond J. Dearie, United States District Court Judge for the Eastern District of New York from 1986 to 1987. Ms. Kanter received her B.S. in Business Administration and Management from the University at Albany School of Business and her J.D. from Brooklyn Law School. - 在根据《交易法》将我们的普通股注册为一类证券生效之前，StacyJ.Kanter立即成为我们的董事会成员。Kanter女士在Skadden，Arps，Slate，Meagher&Flom LLP从事法律执业超过30年，她于1993年至2018年12月担任合伙人，并于2009年至2018年12月担任全球资本市场业务主管，自2019年1月起担任法律顾问。Kanter女士还担任Skadden全球多样性和包容性委员会主席。1984年至1986年和1988年至1993年，Kanter女士是Skadden的合伙人。Kanter女士从1986年到1987年担任纽约东区美国地方法院法官Raymond J.Dearie阁下的书记官。Kanter女士在奥尔巴尼商学院（University at Albany School of Business）获得工商管理学士学位，并在布鲁克林法学院（Brooklyn Law School）获得法学博士学位。
- Stacy J. Kanter,is also currently serving as a member of the board of directors of Oppenheimer Holdings Inc. (NYSE: OPY) since October 2023. Ms. Kanter practiced law for more than 30 years with Skadden, Arps, Slate, Meagher & Flom LLP ("Skadden"), where she was a partner from 1993 until December 2018, Head of the Global Capital Markets practice from 2009 until December 2018 and was Of Counsel from January 2019 until May 2019. Ms. Kanter also chaired Skadden's Global Diversity and Inclusion Committee. Ms. Kanter was an associate at Skadden from 1984 to 1986 and from 1988 to 1993. Ms. Kanter served as a law clerk to the Honorable Raymond J. Dearie, United States District Court Judge for the Eastern District of New York from 1986 to 1987. Ms. Kanter received her B.S. in Business Administration and Management from the University at Albany School of Business and her J.D. from Brooklyn Law School.
- Jay S. Skyler
-
Jay S. Skyler， 硕士学位，MACP，自2002年起担任公司董事。他是佛罗里达州迈阿密大学一名医学、儿科和心理学教授；以及糖尿病研究所副主任，他自1976年就开始在该大学任职。他还担任糖尿病与消化及肾脏疾病1型糖尿病TrialNet临床试验网络全国研究所研究董事长。他曾担任Amylin制药股份有限公司董事，直到2012年8月该公司被百时美施贵宝公司收购；MiniMed有限公司董事，直到2001年该公司被 Medtronic有限公司收购。他持有宾夕法尼亚州立大学学士学位以及杰弗逊医学院硕士学位。
Jay S. Skyler,has served on the board of directors of SAB Biotherapeutics, Inc. (Nasdaq: SABS). Dr. Skyler is a Professor of Medicine, Pediatrics and Psychology and Deputy Director of the Diabetes Research Institute at the University of Miami, where he has been employed since 1976. Dr. Skyler has also served as Study Chairman for the National Institute of Diabetes & Digestive & Kidney Diseases Type 1 Diabetes clinical trials network. He was previously the President of the American Diabetes Association and Vice-President of the International Diabetes Federation. Dr. Skyler previously served as a director of Amylin Pharmaceuticals, Inc., until its acquisition by Bristol-Myers Squibb Company in August 2012, and served as a director of MiniMed, Inc., until its acquisition by Medtronic plc. in 2001. From 2002 to 2023, Dr. Skyler served on the board of directors of DexCom Inc. (Nasdaq: DXCM). Dr. Skyler received a B.S. from Pennsylvania State and an M.D. from Jefferson Medical College. - Jay S. Skyler， 硕士学位，MACP，自2002年起担任公司董事。他是佛罗里达州迈阿密大学一名医学、儿科和心理学教授；以及糖尿病研究所副主任，他自1976年就开始在该大学任职。他还担任糖尿病与消化及肾脏疾病1型糖尿病TrialNet临床试验网络全国研究所研究董事长。他曾担任Amylin制药股份有限公司董事，直到2012年8月该公司被百时美施贵宝公司收购；MiniMed有限公司董事，直到2001年该公司被 Medtronic有限公司收购。他持有宾夕法尼亚州立大学学士学位以及杰弗逊医学院硕士学位。
- Jay S. Skyler,has served on the board of directors of SAB Biotherapeutics, Inc. (Nasdaq: SABS). Dr. Skyler is a Professor of Medicine, Pediatrics and Psychology and Deputy Director of the Diabetes Research Institute at the University of Miami, where he has been employed since 1976. Dr. Skyler has also served as Study Chairman for the National Institute of Diabetes & Digestive & Kidney Diseases Type 1 Diabetes clinical trials network. He was previously the President of the American Diabetes Association and Vice-President of the International Diabetes Federation. Dr. Skyler previously served as a director of Amylin Pharmaceuticals, Inc., until its acquisition by Bristol-Myers Squibb Company in August 2012, and served as a director of MiniMed, Inc., until its acquisition by Medtronic plc. in 2001. From 2002 to 2023, Dr. Skyler served on the board of directors of DexCom Inc. (Nasdaq: DXCM). Dr. Skyler received a B.S. from Pennsylvania State and an M.D. from Jefferson Medical College.
高管简历
中英对照 | 中文 | 英文- Les Funtleyder
Les Funtleyder自2018年12月起担任我们的临时首席财务官，自2016年6月起担任我们的董事会成员。Funtleyder先生还自2014年1月起担任E Squared Capital Management，LLC的梦百合投资组合经理，自2017年6月起担任麦肯锡公司（McKinsey and Co.）的高级外部顾问，自2013年12月起担任私募股权梦百合基金BlueCloud Health的咨询合伙人。Funtleyder之前曾担任Opko Health Inc.（一家公开上市的梦百合公司）战略投资和通信主管。Funtleyder先生目前在几家私营梦百合公司和基金会的董事会任职。Funtleyder先生也是Columbia University Medical Center的兼职教授。Funtleyder先生在杜兰大学（Tulane University）获得学士学位，在哥伦比亚大学邮差公共卫生学院（Columbia University Mailman School of Public Health）获得硕士学位。
Les Funtleyder has served as a member of Board since December 2020. Mr. Funtleyder has served as a member of the board of directors of Applied Therapeutics Inc. (NASDAQ: APLT), a clinical stage biopharmaceutical company, since June 2016 and served as its interim Chief Financial Officer from December 2018 to April 2019. Mr. Funtleyder has also served as a healthcare portfolio manager at E Squared Capital Management, LLC since January 2014, a senior external advisor with McKinsey and Co. since June 2017, and a consulting partner at Bluecloud Health, a private equity healthcare fund, since December 2013. Mr. Funtleyder previoly served as the director of strategic investments and communications of OPKO Health Inc. (NASDAQ: OPK), a publicly traded healthcare company, from April 2014 to June 2016. Mr. Funtleyder currently serves on the board of directors of several private healthcare companies and foundations. Mr. Funtleyder is also an adjunct professor of Healthcare Investing at Columbia University's School of Public Health. Mr. Funtleyder received his B.A. from Tulane University and MPH from Columbia University Mailman School of Public Health.- Les Funtleyder自2018年12月起担任我们的临时首席财务官，自2016年6月起担任我们的董事会成员。Funtleyder先生还自2014年1月起担任E Squared Capital Management，LLC的梦百合投资组合经理，自2017年6月起担任麦肯锡公司（McKinsey and Co.）的高级外部顾问，自2013年12月起担任私募股权梦百合基金BlueCloud Health的咨询合伙人。Funtleyder之前曾担任Opko Health Inc.（一家公开上市的梦百合公司）战略投资和通信主管。Funtleyder先生目前在几家私营梦百合公司和基金会的董事会任职。Funtleyder先生也是Columbia University Medical Center的兼职教授。Funtleyder先生在杜兰大学（Tulane University）获得学士学位，在哥伦比亚大学邮差公共卫生学院（Columbia University Mailman School of Public Health）获得硕士学位。
- Les Funtleyder has served as a member of Board since December 2020. Mr. Funtleyder has served as a member of the board of directors of Applied Therapeutics Inc. (NASDAQ: APLT), a clinical stage biopharmaceutical company, since June 2016 and served as its interim Chief Financial Officer from December 2018 to April 2019. Mr. Funtleyder has also served as a healthcare portfolio manager at E Squared Capital Management, LLC since January 2014, a senior external advisor with McKinsey and Co. since June 2017, and a consulting partner at Bluecloud Health, a private equity healthcare fund, since December 2013. Mr. Funtleyder previoly served as the director of strategic investments and communications of OPKO Health Inc. (NASDAQ: OPK), a publicly traded healthcare company, from April 2014 to June 2016. Mr. Funtleyder currently serves on the board of directors of several private healthcare companies and foundations. Mr. Funtleyder is also an adjunct professor of Healthcare Investing at Columbia University's School of Public Health. Mr. Funtleyder received his B.A. from Tulane University and MPH from Columbia University Mailman School of Public Health.
- Catherine Thorpe
Catherine Thorpe，担任CFGI斯坦福办公室管理合伙人。自2018年以来，索普女士在专业金融咨询公司CFGI担任过各种职务。2016年2月至2018年4月，她在网络安全和数据备份公司Datto，Inc.担任内部审计主管。在此之前，她曾于2007年至2016年担任GE Capital的董事总经理，并于1984年7月至1991年12月以及2004年9月至2007年1月担任普华永道的经理。索普女士拥有西蒙斯大学会计学学士学位，是一名注册会计师。
Catherine Thorpe,serves as the Managing Partner of CFGI Stamford Office. Ms. Thorpe has occupied various roles at CFGI, a specialized financial consulting firm, since 2018. From February 2016 to April 2018, she was the Internal Audit Leader at Datto, Inc., a cybersecurity and data backup company. Prior to that, she was a Managing Director at GE Capital from 2007 to 2016, and from July 1984 to December 1991 and from September 2004 to January 2007 she was a Manager at PricewaterhouseCoopers. Ms. Thorpe holds a bachelor's degree in accounting from Simmons University and is a Certified Public Accountant.- Catherine Thorpe，担任CFGI斯坦福办公室管理合伙人。自2018年以来，索普女士在专业金融咨询公司CFGI担任过各种职务。2016年2月至2018年4月，她在网络安全和数据备份公司Datto，Inc.担任内部审计主管。在此之前，她曾于2007年至2016年担任GE Capital的董事总经理，并于1984年7月至1991年12月以及2004年9月至2007年1月担任普华永道的经理。索普女士拥有西蒙斯大学会计学学士学位，是一名注册会计师。
- Catherine Thorpe,serves as the Managing Partner of CFGI Stamford Office. Ms. Thorpe has occupied various roles at CFGI, a specialized financial consulting firm, since 2018. From February 2016 to April 2018, she was the Internal Audit Leader at Datto, Inc., a cybersecurity and data backup company. Prior to that, she was a Managing Director at GE Capital from 2007 to 2016, and from July 1984 to December 1991 and from September 2004 to January 2007 she was a Manager at PricewaterhouseCoopers. Ms. Thorpe holds a bachelor's degree in accounting from Simmons University and is a Certified Public Accountant.
- Constantine Chinoporos
Constantine Chinoporos，2015年11月至2021年10月担任波士顿制药公司首席商务官。在此之前，他曾在赛诺菲 S.A.、Genzyme、礼来担任业务和企业发展、企业融资、联盟管理等高级职务。他目前担任Apollo Therapeutics的战略顾问，该职位自2023年2月起担任。Chinoporos先生获得了康奈尔大学的历史学本科学位和MBA学位。
Constantine Chinoporos,served as Chief Business Officer at Boston Pharmaceuticals from November 2015 to October 2021. Prior to that, he held senior positions in business and corporate development, corporate finance, and alliance management at Sanofi S.A., Genzyme, and Eli Lilly. He currently serves as a strategic advisor to Apollo Therapeutics, a role which he has held since February 2023. Mr. Chinoporos received an undergraduate degree in History as well as an MBA from Cornell University.- Constantine Chinoporos，2015年11月至2021年10月担任波士顿制药公司首席商务官。在此之前，他曾在赛诺菲 S.A.、Genzyme、礼来担任业务和企业发展、企业融资、联盟管理等高级职务。他目前担任Apollo Therapeutics的战略顾问，该职位自2023年2月起担任。Chinoporos先生获得了康奈尔大学的历史学本科学位和MBA学位。
- Constantine Chinoporos,served as Chief Business Officer at Boston Pharmaceuticals from November 2015 to October 2021. Prior to that, he held senior positions in business and corporate development, corporate finance, and alliance management at Sanofi S.A., Genzyme, and Eli Lilly. He currently serves as a strategic advisor to Apollo Therapeutics, a role which he has held since February 2023. Mr. Chinoporos received an undergraduate degree in History as well as an MBA from Cornell University.
- Dale Hooks
Dale Hooks，在生物制药行业拥有超过30年的经验，领导众多产品发布并管理全球品牌。Hooks先生此前曾于2019年2月至2023年11月在Reata制药公司担任全球商业运营副总裁。在加入Reata之前，Hooks先生于2016年1月至2018年10月担任Clovis肿瘤药物公司的首席商务官，负责建立他们的全球商业组织。从1992年到2014年，Hooks先生在Genentech、Galderma、诺华和GSK担任的职务越来越重要。Hooks先生拥有Stephen F. Austin大学的市场营销和金融学士学位，以及北卡罗来纳大学教堂山分校的工商管理硕士学位。
Dale Hooks,has over 30 years of experience in the biopharma industry, leading numerous product launches and managing global brands. Mr. Hooks previously served as Vice President of Global Commercial Operations at Reata Pharmaceuticals, Inc. from February 2019 to November 2023. Prior to joining Reata, Mr. Hooks was the Chief Commercial Officer at Clovis Oncology, Inc. from January 2016 to October 2018, where he was responsible for building their global commercial organization. From 1992 to 2014, Mr. Hooks held positions of increasing responsibility at Genentech, Galderma, Novartis, and GSK. Mr. Hooks has a B.S. degree in Marketing and Finance from Stephen F. Austin University and an M.B.A. from the University of North Carolina at Chapel Hill.- Dale Hooks，在生物制药行业拥有超过30年的经验，领导众多产品发布并管理全球品牌。Hooks先生此前曾于2019年2月至2023年11月在Reata制药公司担任全球商业运营副总裁。在加入Reata之前，Hooks先生于2016年1月至2018年10月担任Clovis肿瘤药物公司的首席商务官，负责建立他们的全球商业组织。从1992年到2014年，Hooks先生在Genentech、Galderma、诺华和GSK担任的职务越来越重要。Hooks先生拥有Stephen F. Austin大学的市场营销和金融学士学位，以及北卡罗来纳大学教堂山分校的工商管理硕士学位。
- Dale Hooks,has over 30 years of experience in the biopharma industry, leading numerous product launches and managing global brands. Mr. Hooks previously served as Vice President of Global Commercial Operations at Reata Pharmaceuticals, Inc. from February 2019 to November 2023. Prior to joining Reata, Mr. Hooks was the Chief Commercial Officer at Clovis Oncology, Inc. from January 2016 to October 2018, where he was responsible for building their global commercial organization. From 1992 to 2014, Mr. Hooks held positions of increasing responsibility at Genentech, Galderma, Novartis, and GSK. Mr. Hooks has a B.S. degree in Marketing and Finance from Stephen F. Austin University and an M.B.A. from the University of North Carolina at Chapel Hill.
- Evan P. Bailey
Evan P. Bailey，担任执行医疗总监和临床开发高级副总裁。在加入公司之前，Bailey博士曾在福泰制药公司担任医疗总监，并于2019年领导在美国推出用于治疗囊性纤维化（“CF”）的处方药TRIKAFTA，随后担任CF Pipeline的全球医疗主管和CF疾病专家。在此之前，他曾担任马萨诸塞大学医学院儿科助理教授，担任执业儿科肺病学家和CF临床和研究项目的多项临床试验的首席研究员。贝利博士在波士顿儿童医院完成了儿科住院医师实习和儿科肺病学研究金。他在洛约拉大学芝加哥斯特里奇医学院获得医学博士学位，在波士顿大学医学院获得医学科学硕士学位，在波士顿学院获得化学和法语学士学位。
Evan P. Bailey,held the roles of Executive Medical Director and Senior Vice President, Clinical Development. Prior to joining the Company, Dr. Bailey served as Medical Director at Vertex Pharmaceuticals, Inc., where he led the U.S. launch of the prescription drug TRIKAFTA for the treatment of Cystic Fibrosis ("CF") in 2019, then serving as the Global Medical Lead for CF Pipeline and as a CF disease expert. Prior to that, he served as an Assistant Professor of Pediatrics at the University of Massachusetts Medical School, where he was a practicing pediatric pulmonologist and principal investigator for multiple clinical trials running both the CF clinical and research programs. Dr. Bailey completed his residency in Pediatrics and fellowship in Pediatric Pulmonology at Boston Children's Hospital. He obtained his M.D. from Loyola University Chicago Stritch School of Medicine, an M.A. in Medical Sciences from the Boston University School of Medicine and a B.S. in Chemistry and French from Boston College.- Evan P. Bailey，担任执行医疗总监和临床开发高级副总裁。在加入公司之前，Bailey博士曾在福泰制药公司担任医疗总监，并于2019年领导在美国推出用于治疗囊性纤维化（“CF”）的处方药TRIKAFTA，随后担任CF Pipeline的全球医疗主管和CF疾病专家。在此之前，他曾担任马萨诸塞大学医学院儿科助理教授，担任执业儿科肺病学家和CF临床和研究项目的多项临床试验的首席研究员。贝利博士在波士顿儿童医院完成了儿科住院医师实习和儿科肺病学研究金。他在洛约拉大学芝加哥斯特里奇医学院获得医学博士学位，在波士顿大学医学院获得医学科学硕士学位，在波士顿学院获得化学和法语学士学位。
- Evan P. Bailey,held the roles of Executive Medical Director and Senior Vice President, Clinical Development. Prior to joining the Company, Dr. Bailey served as Medical Director at Vertex Pharmaceuticals, Inc., where he led the U.S. launch of the prescription drug TRIKAFTA for the treatment of Cystic Fibrosis ("CF") in 2019, then serving as the Global Medical Lead for CF Pipeline and as a CF disease expert. Prior to that, he served as an Assistant Professor of Pediatrics at the University of Massachusetts Medical School, where he was a practicing pediatric pulmonologist and principal investigator for multiple clinical trials running both the CF clinical and research programs. Dr. Bailey completed his residency in Pediatrics and fellowship in Pediatric Pulmonology at Boston Children's Hospital. He obtained his M.D. from Loyola University Chicago Stritch School of Medicine, an M.A. in Medical Sciences from the Boston University School of Medicine and a B.S. in Chemistry and French from Boston College.